Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Change in Cash: 2022-2025

Historic Change in Cash for Taysha Gene Therapies (TSHA) over the last 4 years, with Sep 2025 value amounting to -$15.4 million.

  • Taysha Gene Therapies' Change in Cash fell 2.40% to -$15.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $139.7 million, marking a year-over-year increase of 2207.38%. This contributed to the annual value of -$4.9 million for FY2024, which is 108.75% down from last year.
  • Per Taysha Gene Therapies' latest filing, its Change in Cash stood at -$15.4 million for Q3 2025, which was down 107.86% from $196.2 million recorded in Q2 2025.
  • In the past 5 years, Taysha Gene Therapies' Change in Cash registered a high of $196.2 million during Q2 2025, and its lowest value of -$52.5 million during Q1 2022.
  • Over the past 3 years, Taysha Gene Therapies' median Change in Cash value was -$18.3 million (recorded in 2023), while the average stood at $19.0 million.
  • Examining YoY changes over the last 5 years, Taysha Gene Therapies' Change in Cash showed a top increase of 473.27% in 2023 and a maximum decrease of 138.03% in 2023.
  • Taysha Gene Therapies' Change in Cash (Quarterly) stood at $53.6 million in 2022, then plummeted by 138.03% to -$20.4 million in 2023, then increased by 8.46% to -$18.7 million in 2024, then declined by 2.40% to -$15.4 million in 2025.
  • Its Change in Cash stands at -$15.4 million for Q3 2025, versus $196.2 million for Q2 2025 and -$22.4 million for Q1 2025.